TY - JOUR
T1 - Dual anti-viral treatment for persistent COVID-19 in immunocompromised hemato-oncological patients is associated with a favorable prognosis and minor side effects
AU - Meijer, Suzy E.
AU - Halutz, Ora
AU - Adler, Amos
AU - Levytskyi, Katya
AU - Tau, Luba
AU - Dekel, Michal
AU - Cohen-Poradosu, Ronit
AU - Katchman, Evgene
AU - Shasha, David
AU - Ablin, Jacob
AU - Choshen, Guy
AU - Jacob, Giris
AU - Wasserman, Asaf
AU - Ingbir, Merav
AU - Cohen, Yael C.
AU - Perry, Chava
AU - Ram, Ron
AU - Herishanu, Yair
AU - Bar On, Yael
AU - van Thijn, Elma
AU - Rutsinsky, Natalie
AU - Harari, Sheri
AU - Stern, Adi
AU - Ben-Ami, Ronen
AU - Paran, Yael
N1 - Publisher Copyright:
© 2023 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control
PY - 2024/3
Y1 - 2024/3
N2 - In hemato-oncological patients, COVID-19 can present as a persistent infection with ongoing symptoms and viral replication over a prolonged period of time. Data are scarce on the preferred treatment options for these patients. We describe our experience with a five-day course of dual anti-viral treatment with remdesivir and nirmatrelvir/ritonavir for hemato-oncological immunocompromised patients with persistent COVID-19. Fifteen patients with a history of lymphoma, CLL, and MM were included. Eight were male, median age was 74. All patients had an immediate clinical and virological response. In 73 % of patients, PCR for SARS-CoV-2 became negative at the end of treatment and the rest had an increase in PCR cycle threshold (CT) values, with a median increase of 6 cycles. After a follow-up of three months, 60 % of patients remained in full clinical and virological remission. None required invasive mechanical ventilation or died. The side effects we observed, neutropenia, lactatemia and elevated transaminases, were mild and almost all transient in nature. We conclude that dual anti-viral treatment appears to be a valid treatment option for persistent COVID-19.
AB - In hemato-oncological patients, COVID-19 can present as a persistent infection with ongoing symptoms and viral replication over a prolonged period of time. Data are scarce on the preferred treatment options for these patients. We describe our experience with a five-day course of dual anti-viral treatment with remdesivir and nirmatrelvir/ritonavir for hemato-oncological immunocompromised patients with persistent COVID-19. Fifteen patients with a history of lymphoma, CLL, and MM were included. Eight were male, median age was 74. All patients had an immediate clinical and virological response. In 73 % of patients, PCR for SARS-CoV-2 became negative at the end of treatment and the rest had an increase in PCR cycle threshold (CT) values, with a median increase of 6 cycles. After a follow-up of three months, 60 % of patients remained in full clinical and virological remission. None required invasive mechanical ventilation or died. The side effects we observed, neutropenia, lactatemia and elevated transaminases, were mild and almost all transient in nature. We conclude that dual anti-viral treatment appears to be a valid treatment option for persistent COVID-19.
KW - Dual anti-viral therapy
KW - Hemato-oncological patients
KW - Immunocompromised patients
KW - Persistent COVID-19
UR - http://www.scopus.com/inward/record.url?scp=85176411005&partnerID=8YFLogxK
U2 - 10.1016/j.jiac.2023.10.022
DO - 10.1016/j.jiac.2023.10.022
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37944697
AN - SCOPUS:85176411005
SN - 1341-321X
VL - 30
SP - 271
EP - 275
JO - Journal of Infection and Chemotherapy
JF - Journal of Infection and Chemotherapy
IS - 3
ER -